Last reviewed · How we verify
NCT03667222: PRISM
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
Phase 2 trial testing minocycline topical gel in Papulopustular Rosacea in 207 participants. Status unknown.
17 May 2019
Quick facts
| Lead sponsor | BioPharmX, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 207 |
| Start date | 18 September 2018 |
| Primary completion | 17 May 2019 |
| Estimated completion | 17 August 2019 |
| Sites | 12 locations across United States |
Drugs / interventions tested
- minocycline topical gel — full drug profile →
- topical gel vehicle
Conditions studied
- Papulopustular Rosacea — all drugs for Papulopustular Rosacea →
Sponsor
BioPharmX, Inc. — full company profile →
Who can join
18 and older, any sex, with Papulopustular Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea.
Martins AM, Marto JM, Johnson JL, Graber EM. · · 2021 · cited 48× · PMID 34206485 · DOI 10.3390/antibiotics10070757
Verify or expand the search:
- PubMed search for NCT03667222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Papulopustular Rosacea
Currently open trials in the same condition.
- NCT06952517 — Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea · Phase 2 · recruiting
Other BioPharmX, Inc. trials
Trials by the same sponsor.
- NCT03050086 — Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea · Phase 1, PHASE2 · completed
- NCT02946788 — Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03667222 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioPharmX, Inc.
- Last refreshed: 10 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03667222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing